Hanmi Pharm. Co., Ltd. (KRX:128940)

South Korea flag South Korea · Delayed Price · Currency is KRW
300,500
-5,500 (-1.80%)
At close: May 28, 2025, 3:30 PM KST
3.26%
Market Cap 3.95T
Revenue (ttm) 1.48T
Net Income (ttm) 108.92B
Shares Out 12.68M
EPS (ttm) 8,589.65
PE Ratio 36.26
Forward PE 24.45
Dividend 1,250.00 (0.41%)
Ex-Dividend Date Jun 27, 2025
Volume 65,864
Average Volume 98,364
Open 311,500
Previous Close 306,000
Day's Range 298,000 - 311,500
52-Week Range 214,500 - 375,000
Beta 0.64
RSI 72.46
Earnings Date Jul 29, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha... [Read more]

Sector Healthcare
Founded 1973
Employees 2,330
Stock Exchange Korea Stock Exchange
Ticker Symbol 128940
Full Company Profile

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.

Financial Statements

News

There is no news available yet.